BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 3871853)

  • 1. Inhibition of types A and B monoamine oxidase by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Fuller RW; Hemrick-Luecke SK
    J Pharmacol Exp Ther; 1985 Mar; 232(3):696-701. PubMed ID: 3871853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the effects of two 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs, 1-methyl-4-(2-thienyl)-1,2,3,6-tetrahydropyridine and 1-methyl-4-(3-thienyl)-1,2,3,6-tetrahydropyridine, on monoamine oxidase in vitro and on dopamine in mouse brain.
    Fuller RW; Robertson DW; Hemrick-Luecke SK
    J Pharmacol Exp Ther; 1987 Feb; 240(2):415-20. PubMed ID: 3100775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S; Zheng H; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of amfonelic acid, alpha-methyltyrosine, Ro 4-1284 and haloperidol pretreatment on the depletion of striatal dopamine by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
    Fuller RW; Hemrick-Luecke SK
    Res Commun Chem Pathol Pharmacol; 1985 Apr; 48(1):17-25. PubMed ID: 3873102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A reactive metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is formed in rat brain in vitro by type B monoamine oxidase.
    Corsini GU; Pintus S; Bocchetta A; Piccardi MP; Del Zompo M
    J Pharmacol Exp Ther; 1986 Aug; 238(2):648-52. PubMed ID: 3488394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-dependent effects of the 2'-methyl analog of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine: prevention by inhibitors of monoamine oxidase B.
    Finnegan KT; Irwin I; Delanney LE; Langston JW
    J Pharmacol Exp Ther; 1995 May; 273(2):716-20. PubMed ID: 7752075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
    Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depletion of heart norepinephrine in mice by some analogs of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).
    Fuller RW; Hemrick-Luecke SK
    Res Commun Chem Pathol Pharmacol; 1987 May; 56(2):147-56. PubMed ID: 3496637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 1-methyl-4-(p-chlorophenyl)-1,2,3,6-tetrahydropyridine, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and p-chloroamphetamine as monoamine depletors.
    Fuller RW; Hemrick-Luecke SK; Robertson DW
    Res Commun Chem Pathol Pharmacol; 1985 Oct; 50(1):57-65. PubMed ID: 2417293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) binding sites in C57BL/6 mouse brain: mutual effects of monoamine oxidase inhibitors and sigma ligands on MPTP and sigma binding sites.
    Itzhak Y; Mash D; Zhang SH; Stein I
    Mol Pharmacol; 1991 Mar; 39(3):385-93. PubMed ID: 1848660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different effects of monoamine oxidase inhibition on MPTP depletion of heart and brain catecholamines in mice.
    Fuller RW; Hemrick-Luecke SK; Kindt MV; Heikkila RE
    Life Sci; 1988; 42(3):263-71. PubMed ID: 3121972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-dependent effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): correlation with monoamine oxidase-B.
    Walsh SL; Wagner GC
    Synapse; 1989; 3(4):308-14. PubMed ID: 2787063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Participation of brain monoamine oxidase B form in the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: relationship between the enzyme inhibition and the neurotoxicity.
    Kinemuchi H; Arai Y; Toyoshima Y
    Neurosci Lett; 1985 Jul; 58(2):195-200. PubMed ID: 3876524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors.
    Heikkila RE; Manzino L; Cabbat FS; Duvoisin RC
    Nature; 1984 Oct 4-10; 311(5985):467-9. PubMed ID: 6332989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. I. Evaluation of the biological activity of MPTP analogs.
    Youngster SK; Sonsalla PK; Sieber BA; Heikkila RE
    J Pharmacol Exp Ther; 1989 Jun; 249(3):820-8. PubMed ID: 2786564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the mouse.
    Sonsalla PK; Youngster SK; Kindt MV; Heikkila RE
    J Pharmacol Exp Ther; 1987 Sep; 242(3):850-7. PubMed ID: 2888874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primate-rodent 3H-MPTP binding differences, and biotransformation of MPTP to a reactive intermediate in vitro.
    Corsini GU; Pintus S; Bocchetta A; Piccardi MP; Del Zompo M
    J Neural Transm Suppl; 1986; 22():55-60. PubMed ID: 3097260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central and peripheral catecholamine depletion by 1-methyl-4-phenyl-tetrahydropyridine (MPTP) in rodents.
    Fuller RW; Steranka LR
    Life Sci; 1985 Jan; 36(3):243-7. PubMed ID: 3871244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoamine oxidase-A inhibitors and dopamine metabolism in rat caudatus: evidence that an increased cytosolic level of dopamine displaces reversible monoamine oxidase-A inhibitors in vivo.
    Colzi A; D'Agostini F; Cesura AM; Borroni E; Da Prada M
    J Pharmacol Exp Ther; 1993 Apr; 265(1):103-11. PubMed ID: 8473998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective rather than neurorescue or neurorestorative effect of selegiline against MPTP-induced dopaminergic toxicity.
    Wu WR; Zhu XZ; Guan HJ; Wang RG; Ji XQ
    Zhongguo Yao Li Xue Bao; 1999 Feb; 20(2):146-50. PubMed ID: 10437162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.